## **RSC Chemical Biology**



## CORRECTION

View Article Online



## **Correction: Fragment-based covalent** ligand discovery

Cite this: RSC Chem. Biol., 2021,

Wenchao Lu, ab Milka Kostic, a Tinghu Zhang, ab Jianwei Che, abc Matthew P. Patricelli, Lyn H. Jones, Edward T. Chouchaniae and Nathanael S. Gray\*ab

DOI: 10.1039/d1cb90008k

Correction for 'Fragment-based covalent ligand discovery' by Wenchao Lu et al., RSC Chem. Biol., 2021, DOI: 10.1039/d0cb00222d.

rsc.li/rsc-chembio

The authors regret that an incorrect version of Fig. 2 was included in the original article, where the structure of Sulfopin in Fig. 2D was incorrectly shown. The correct version of Fig. 2 is presented below.

<sup>&</sup>lt;sup>a</sup> Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. E-mail: nathanael\_gray@dfci.harvard.edu

<sup>&</sup>lt;sup>b</sup> Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02215, USA

<sup>&</sup>lt;sup>c</sup> Center for Protein Degradation, Dana-Farber Cancer Institute, Boston, MA 02215, USA

<sup>&</sup>lt;sup>d</sup> Vividion Therapeutics, La Jolla, CA 92121, USA

<sup>&</sup>lt;sup>e</sup> Department of Cell Biology, Harvard Medical School, Boston, MA 02215, USA

Correction




Fig. 2 The structures of representative well-characterized electrophilic fragments identified from target-based screening strategies in recent years. (A) KRAS-G12C allele-specific covalent fragment (6H05) identified from tethering screen, which was further elaborated to compound 12.31 This inspired numerous groups to develop further optimized inhibitors, within which AMG510<sup>33</sup> and MRTX849<sup>36</sup> successfully entered clinical trials. (B) Compound 5 targets the active cysteine (C885) of HOIP.<sup>37</sup> (C) OTUB2-COV-1 targets the active cysteine (C51) of OTUB2 and NUDT7-COV-1 target C73 of NUDT7.<sup>38</sup> (D) Sulfopin targets the active cysteine of Pin1 (C113).<sup>39</sup> (E) Representative covalent fragment scaffolds target the active cysteine (C145) of SARS-COV-2 main protease (Mpro).40

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.